Updates are available Correction dated 2022-12-22

Article History

Received: 11 March 2021

Accepted: 26 August 2021

First Online: 16 September 2021

Change Date: 22 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s12877-022-03486-6

Declarations

:

: For participation, a signed informed consent was needed. NH personnel assessed the patients’ capacity to consent to participate in the study. For patients with a clear capacity to consent, a signed informed consent was collected directly from the participants, but not from their next of kin. For patients with no capacity to consent, a signed informed consent from the participants’ next of kin was collected. The Regional Committee for Medical and Health Research Ethics in South-Eastern Norway approved the study (2011/1738). The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations.

: Not applicable.

: GS has received honoraria for participating in a meeting of the Norwegian advisory board for Biogen, regarding the aducanumab trials. The other named authors have no competing interests, financial or otherwise.